Special Issue "The Role of NK and T Cells in Cancer"
Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 17885
Interests: NK cells; immunosenescence; T and NK cell-based immunotherapy; leukemia; melanoma
Special Issues, Collections and Topics in MDPI journals
Advances in the last decade strongly support the relevance of the immune system in surveillance against cancer and mechanisms used by cancer cells to evade immunosurveillance. Thus, immunotherapy against cancer is an evolving area of basic and clinical research. Current immunotherapies aimed at restoring and improving T cell activation, such as blocking immune checkpoints or using CAR-T cells, have emerged as pillars of personalized therapies against different types of cancer. Although clinical trials with CAR-T cells have shown encouraging results in hematologic malignancies, it has also been reported that toxicity associated with CAR-T can induce severe adverse effects in the patients and, occasionally, patient death. In addition to T cells, the use of natural killer cells (NK) has recently become important among new cancer immunotherapies based on the adoptive transfer of autologous or allogeneic NK cells. The anti-tumor potential of NK cells can be enhanced by blocking immune checkpoints, such as KIR or NKG2A, by using cytokines or by using tumor-specific antibodies to induce ADCC. In addition, the development of CAR-NK cells may open new possibilities for the treatment of cancer with fewer side effects than CAR-T. The use of bi-, tri-, or poly-specific monoclonal antibodies and engagers also increases the binding of T and NK cells to tumor cells and increases tumor lysis. The future of combined treatments that include different types of immunotherapies and other treatment modalities is being explored.
Thus, the aim of this Special Issue is to highlight recent studies on the mechanisms used by cancer cells to escape immune surveillance and advances in T and NK cell-based immunotherapies.
Prof. Dr. Raquel Tarazona
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- NK cells
- T cells